Mary M. Rozenman, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 30,000 shares at $22.50 ($675K) on 2017-09-07, disclosed to the SEC on 2017-09-11.
Open-market sale of $675k AIMT by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AIMT | SELL | 2018-01-04 | $489K | — | Filing → |
| AIMT | SELL | 2017-12-28 | $381K | — | Filing → |
| AIMT | SELL | 2017-07-17 | $320K | — | Filing → |